A Short-Length Peptide YY Analogue with Anorectic Effect in Mice

May 18, 2017 - Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan. ACS Omega , 2017, 2 (5), pp 2200–220...
0 downloads 6 Views 902KB Size
Download PDF
This is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.

Article http://pubs.acs.org/journal/acsodf

A Short-Length Peptide YY Analogue with Anorectic Effect in Mice Naoki Nishizawa, Ayumu Niida, Yasushi Masuda, Satoshi Kumano, Kotaro Yokoyama, Hideki Hirabayashi, Nobuyuki Amano, Tetsuya Ohtaki, and Taiji Asami* Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., Fujisawa 251-8555, Japan S Supporting Information *

ABSTRACT: Peripheral administration of PYY3−36, a fragment of peptide YY (PYY), has been reported to reduce food intake by activating the neuropeptide Y2 receptor (Y2R). An Nterminally truncated PYY analogue, benzoyl-[Ala26,Ile28,31]PYY(25−36) (1), showed a relatively potent agonist activity for Y2R but a weak anorectic activity by intraperitoneal administration (2000 nmol/kg) in lean mice because of its markedly poor biological stability in the mouse serum. Notably, two cyclohexylalanine (Cha) substitutions for Tyr residues at positions 27 and 36 (4) improved the stability in the mouse serum concomitant with enhanced anorectic activity. Further optimization at positions 27, 28, 30, and 31 revealed that 21, containing Cha28 and Aib31 residues, showed a more potent anorectic activity than PYY3−36 at a low dose of 300 nmol/kg. The minimum effective dose by intraperitoneal administration of 21 was 30 nmol/kg (ca. 52 μg/kg) in mice, suggesting the biologic potential of short-length PYY3−36 analogues with a potent anorectic effect.

■

INTRODUCTION Obesity is considered to comprise an incredibly multifactorial chronic disease based on both genetic and behavioral factors.1−3 Obesity is commonly associated with various diseases, such as diabetes mellitus, hypertension, stroke, cardiovascular disease, disability, gallbladder disease, osteoarthritis, sleep apnea, and certain types of cancer.1 In addition, obesity, which is associated with an increased risk for cardiovascular and all-cause mortality, has been recognized as a worldwide epidemic.2,4 When considering the treatment of obesity, it is required that the energy intake is decreased and/or the energy expenditure is increased to decrease the adipose tissue mass through the generation of a negative overall energy balance. For this, a restricted diet and exercise therapy represent the primary options; however, current nutritional guidance and behavioral approaches have not consistently yielded successful results. Thus, the establishment of an efficient therapy to treat metabolic disease and the development of novel effective drugs for obesity are strongly desired. Known mechanisms for regulating food intake and energy metabolism in the body include anorectic peptides, their receptors, and functional relationships.5,6 Among these, peptide YY (PYY, Tyr-Pro-Ile-Lys-Pro-Glu-Ala-Pro-Gly-Glu-Asp-AlaSer-Pro-Glu-Glu-Leu-Asn-Arg-Tyr-Tyr-Ala-Ser-Leu-Arg-HisTyr-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH2) was originally isolated from the porcine intestine as it possessed structural identity to neuropeptide Y (NPY) and pancreatic polypeptide (PP).7,8 These three peptides form the NPY peptide family, comprising peptides composed of 36 amino acid residues, a Tyr-rich structure, and a C-terminal amide group. © 2017 American Chemical Society

The homologies of PYY/NPY, PYY/PP, and NPY/PP are 70, 70, and approximately 50%, respectively.9,10 NPY family receptors including six subtypes (Y1−Y5 and y6) are recognized in mammals. However, the functionality of Y3 remains controversial,11−13 and the gene for y6 is not expressed in primates.14−16 Therefore, most pharmacological studies of the NPY family receptors have focused on Y1, Y2, Y4, and Y5, clarifying their different distributions and ligand affinities.8,17−19 PYY is produced and secreted from L-cells in the intestinal epithelium of the ileum and colon. PYY has two endogenous isoforms: PYY1−36 and its N-terminally truncated form, PYY3−36, which constitutes the main isoform in circulation. The N-terminal dipeptide (Tyr-Pro) of PYY1−36 is considered to be cleaved by a plasma protease, dipeptidyl peptidase IV.20 PYY1−36 binds to all Y family receptors with comparable affinity of a similar magnitude; conversely, PYY3−36 displays increased Y2 receptor (Y2R) affinity and decreased Y1R and Y5R affinity.21,22 Notably, PYY3−36 has been reported to show anorectic activity by central and peripheral administration in mice.23 The anorectic effect was not observed in Y2R KO mice, indicating that the effect was mediated by Y2R activation.24 In initial clinical trials, approximately 30% of energy intake was suppressed after continuous intravenous infusion of PYY3−36;25 in addition, an anorectic effect of PYY3−36 was also found in subsequent clinical trials.26,27 Received: March 4, 2017 Accepted: May 8, 2017 Published: May 18, 2017 2200

DOI: 10.1021/acsomega.7b00258 ACS Omega 2017, 2, 2200−2207

2201

benzoyl benzoyl benzoyl benzoyl benzoyl benzoyl benzoyl benzoyl benzoyl benzoyl benzoyl benzoyl cyclohexylcarbonyl cyclohexylcarbonyl benzoyl cyclohexylcarbonyl cyclohexylcarbonyl benzoyl benzoyl benzoyl benzoyl cyclohexylcarbonyl isobutanoyl 4-aminomethylbenzoyl 1-naphthoyl 2-naphthoyl cyclohexylcarbonyl cyclohexylcarbonyl cyclohexylcarbonyl

PYY3−36 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Ala Ala His His His His His His His His His His His His His His His His His His His His His His His His His His His

AA26 Tyr Tyr Cha Cha Cha Cha Cha Cha Cha Cha Cha Cha Cha Cha Nal(2) Cha Cha Cha Cha Cha Cha Cha Cha Cha Cha Cha Cha Cha Nal(2)

AA27 Ile Ile Ile Ile Ile Ile Ile Ile Ile Ile Ile Ile Ile Cha Ile Ile Ile Trp Nal(1) Nal(2) Cha Cha Cha Cha Cha Cha Cha Cha Cha

AA28 Leu Leu Leu Leu Trp Phe(4F) Leu Leu Leu Leu Trp Trp Trp Trp Trp Leu Trp Leu Leu Leu Leu Leu Leu Leu Leu Leu Trp Phe(4F) Leu

AA30 Ile Ile Ile Ile Ile Ile Nle Cha Lys Aib Aib Lys Ile Ile Ile Aib Aib Aib Aib Aib Aib Aib Aib Aib Aib Aib Aib Aib Aib

AA31 Tyr Cha Tyr Cha Cha Cha Cha Cha Cha Cha Cha Cha Cha Cha Cha Cha Cha Cha Cha Cha Cha Cha Cha Cha Cha Cha Cha Cha Cha

AA36 0.30 16 (9.6−27) 3.2 (2.0−5.0) 15 (9.0−24) 7.2 (4.5−12) 9.8 (6.3−15) 11 (5.5−23) 13 (7.8−20) 25 (16−39) 1.6 (1.3−1.9) 4.8 (3.4−6.9) 11 (7.1−18) 2.4 (1.8−3.3) 6.8 (5.3−8.6) 15 (8.2−26) 19 (13−28) 4.9 (2.8−8.7) 5.7 (3.5−9.2) 6.4 (4.7−8.7) 9.1 (4.9−17) 29 (17−48) 7.4 (4.3−13) 11 (6.2−19) 3.1 (2.2−4.4) 0.65 (0.50−0.79) 18 (9.8−34) 26 (16−41) 8.9 (5.6−14) 31 (19−49) 18 (10−33)

0.13 1.7 (1.3−2.2) 1.1 (0.68−1.7) 1.9 (0.78−4.7) 3.6 (2.4−5.4) 2.3 (1.3−4.4) 2.9 (1.7−4.9) 2.4 (1.1−5.5) 7.3 (3.7−14) 0.62 (0.40−0.97) 1.1 (0.68−1.7) 2.4 (1.4−4.1) 0.84 (0.59−1.2) 1.7 (0.79−3.9) 11 (5.2−23) 7.3 (4.2−13) 1.6 (0.92−2.6) 1.9 (1.3−2.8) 1.6 (1.0−2.3) 2.7 (1.5−5.0) 7.5 (4.5−13) 2.0 (1.2−3.3) 4.0 (2.0−8.0) 1.2 (0.77−1.9) 0.48 (0.36−0.65) 5.8 (3.0−11) 6.0 (2.9−12) 2.2 (1.3−3.8) 7.2 (4.8−11) 14 (9.0−20)

EC50b nM (95% CI)

IC50a nM (95% CI) ND 25 ± 21 ± 39 ± ND 65 ± ND ND ND ND 60 ± 52 ± ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 7 5

5

7 5 7

2000

500 33 ± 6 ND ND ND ND 8±7 18 ± 5 ND 17 ± 8 ND 8±7 12 ± 3 ND 8±6 23 ± 7 19 ± 7 5 ± 13 24 ± 5 2±8 41 ± 5 18 ± 2 49 ± 4 25 ± 7 20 ± 11 29 ± 7 ND ND 12 ± 8 21 ± 7 28 ± 8

1000 45 ± 6 ND ND 17 ± 7 34 ± 6 40 ± 2 40 ± 5 12 ± 5 46 ± 8 −15 ± 7 39 ± 3 36 ± 8 4 ± 13 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND

bolus dosing (nmol/kg)

% food intake inhibitionc

24 ± 5 ND ND ND ND 10 ± 4 ND ND ND ND 3±4 ND ND ND ND ND ND ND ND ND ND 32 ± 3 ND 14 ± 7 ND ND ND ND ND ND

250

81 5 53 10 102 93 96 ND 114 ND 94 95 51 ND ND 100 ND ND ND ND ND ND ND ND ND ND ND ND ND ND

residual ratio (%)d

stability in mouse serum

a IC50 values and 95% confidence intervals (CI) of peptide analogues represent the concentrations required to displace the binding of the radiolabeled ligand by 50%. The IC50 value of PYY3−36 is calculated as the average value of 19 independent experiments. bEC50 values and 95% CI of agonist activities were determined as the concentrations of peptide analogues that induced 50% of the maximum [35S]GTPγS binding. The EC50 value of PYY3−36 is calculated as the average value of 19 independent experiments. cPercentage inhibition of food intake 3 h after administration of peptide analogues at doses of 250, 500, 1000, and 2000 nmol/kg, as compared to that after ip injection with saline as a vehicle in male C57BL/6J mice. Data are expressed as mean ± SD (n = 5−6 per group). ND: not determined. dResidual ratio after 30 min of incubation in 20% mouse serum/phosphate-buffered saline (PBS) at 37 °C. ND: not determined.

R

compound

agonist activity

binding affinity

R-Arg-AA26-AA27-AA28-Asn-AA30-AA31-Thr-Arg-Gln-Arg-AA36-NH2

Table 1. Biological Activities of Dodecapeptide PYY Analogues Substituted at the N-Terminus and at Positions 26, 27, 28, 30, 31, and 36

ACS Omega Article

DOI: 10.1021/acsomega.7b00258 ACS Omega 2017, 2, 2200−2207

ACS Omega

Article

positions 27 or 36. Compounds 2 (Cha36) and 3 (Cha27) showed good profiles of binding affinity and agonist activity for Y2R, as did 1. The serum stability of both 2 and 3 was increased with residual ratio values of 53 and 10%, respectively, indicating the increase in protease resistance effected by the substitution of Cha for Tyr. In addition, the combined Cha substitution at positions 27 and 36 (4) achieved further improvement of serum stability; in particular, 4 did not yield any apparent metabolites within 30 min in 20% mouse serum/ PBS. Consistent with the enhanced stability afforded by the double-Cha substitution, 4 exerted an anorectic activity at a lower dose of 1000 nmol/kg but only minimally affected in vitro agonist activities. Design and Syntheses of Dodecapeptide PYY Analogues Substituted at Position 30 or 31. Further improvement of anorectic activity was investigated by generating amino acid substitutions at positions 30 and 31, which were found to be replaceable without loss of agonist activity for Y2R in our studies (data not shown). Specifically, aromatic amino acid substitutions at position 30, such as Trp (5) or Phe(4F) (6), induced comparable or slightly stronger food intake inhibition than 4, whereas the binding affinities and agonist activities of 5 and 6 were moderate. The results imply that these hydrophobic residue substitutions improved the pharmacokinetic profiles of the peptides. Substitutions of unnatural amino acids Nle31 (7) and Cha31 (8) decreased the binding affinity several-fold compared with 4; however, 8 showed slightly improved anorectic activity. In addition, a Lys analogue (9) displayed more than 4-fold increase in the agonist activity compared to that of 4 but no remarkable anorectic activity, which was likely caused by its decreased serum stability. The introduction of an α,αdisubstituted amino acid, 2-aminoisobutyric acid (Aib), into position 31 (10), which was expected to improve serum stability, increased both agonist activity and anorectic activity. Furthermore, the Aib31 residue, which is known to enhance peptide helicity, may have contributed to inducing a preferable conformation for Y2R recognition and to the resistance against serum proteases. Comparison of the Biological Activities of Peptide Analogues with the Combination of Amino Acid Substitutions at Positions 30 and 31. Substitution of Trp30 (5), Lys31 (9), or Aib31 (10) contributed to the increase in in vitro or in vivo activity, which allowed us to synthesize analogues with combined substitutions at positions 30 and 31. The Trp30-Aib31 analogue (11) showed a moderate anorectic activity comparable to the parent compounds (5, 10). Compound 12 containing Trp30 and Lys31 substitutions, each of which individually showed increased in vivo or in vitro activity, exhibited potent in vitro activities; however, it was not taken into consideration for further studies of Lys31 derivatives owing to its weak anorectic activity. Among the analogues composed of amino acids at positions 30 (Leu or Trp) and 31 (Ile, Lys, or Aib), Leu30-Ile31 (4), Trp30-Ile31 (5), Leu30-Aib31 (10), and Trp30-Aib31 (11) showed similar anorectic activities at 1000 nmol/kg, which was more potent than that shown by the lead compound, 1, at 2000 nmol/kg, concomitant with their enhanced metabolic stability (4, 5, 10, 11) in 20% mouse serum/PBS compared to that in 1. Cha substitutions at positions 27 and 36 (4) were crucial for stability in the mouse serum, and additional substitutions, that is, Trp30 (5), Aib31 (10), and their combination, Trp30-Aib31 (11), allowed the maintenance of high stability. Compounds 4, 5, 10, and 11

Considering that PYY3−36 possesses a weak agonist activity for Y1R and Y4R,22 we were interested in determining the anorectic potential of PYY analogues with potent Y2R agonist activity and higher selectivity for Y2R over Y1R and Y4R. The selectivity of PYY analogues for Y2R has been shown to be increased by N-terminal truncation;28 in addition, amino acid substitutions at positions 32 and 34 in the NPY analogues affect the selectivity for Y1R and Y4R.29,30 Among the reported peptides, 12-amino acid peptides containing the N-terminal benzoyl group showed potent Y2R agonist activity and strict selectivity for Y2R over Y1R and Y5R.31 Specifically, a series of N-terminally substituted benzoylated PYY analogues with 12 amino acids possessed high agonist activities with EC50 values in the nM range for Y2R and selectivity over Y1R and Y5R, for example, benzoyl (6 nM) and 4-aminobenzoyl (3 nM).31 A variety of PYY analogues with amino acid substitutions, such as Ala26 or Ile28,31, were also disclosed to have Y2R agonism.32 Furthermore, PEGylation of the N-terminus of the short-length peptides maintained the selectivity for Y2R and elicited food intake and body weight reduction as well as improved glucose metabolism in rodents.33−35 However, few studies have used the in vivo activity of short-length peptides without the modification with PEG, albumin, or long-chain alkyl groups. We therefore designed and synthesized a new class of shortlength PYY analogues with improved pharmacokinetic profiles as well as potent Y2R agonist activity, and demonstrated their anorectic activity in mice.

■

RESULTS AND DISCUSSION Chemistry. All peptides were synthesized using standard Fmoc-based solid-phase synthetic methods. Subsequent preparative high-performance liquid chromatography (HPLC) purification of the obtained crude peptides exhibited ≥95% homogeneity. The purity of each peptide was verified by analytical reversed-phase HPLC (RP-HPLC), and the structure was assigned using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS). Biological Activities. The binding affinity and agonist activity of all peptides synthesized were examined by receptor and [35S]GTPγS binding assays using Chinese hamster ovary (CHO) cells expressing human cloned Y2R. Peptides with potent agonist activity were then screened for their anorectic activity in mice by intraperitoneal (ip) administration (250, 500, 1000, or 2000 nmol/kg). Results of in vitro and in vivo screening are shown in Table 1. Design and Syntheses of Dodecapeptide PYY Analogues Substituted at Positions 27 and 36. A short-length analogue of PYY3−36 with a simple benzoyl group at the Nterminus, benzoyl-[Ala26,Ile28,31]PYY(25−36) (1), showed relatively high affinity and potent agonist activity for Y2R. Although 1 comprised the short-length peptide without any modification, for example, PEG or a long-chain alkyl, 1 showed moderate anorectic activity by ip administration at a high dose of 2000 nmol/kg in lean mice. Generally, short-length peptides tend to be quickly inactivated by proteases in the serum; therefore, we examined the serum stability of 1. Upon incubation in 20% mouse serum/PBS for 30 min, the residual ratio of the original peptide (1) was 5%. This result indicated the possibility that improvement of the serum stability might provide short-length peptides with a robust anorectic activity. To examine the effect of the substitution for a Tyr residue, which is a target of chymotrypsin-like proteases, on the serum stability, the unnatural amino acid, Cha, was introduced into 2202

DOI: 10.1021/acsomega.7b00258 ACS Omega 2017, 2, 2200−2207

ACS Omega

Article

were comparable to or more stable than PYY3−36 in 20% mouse serum/PBS; 4, 5, 10, and 11 showed, however, lower anorectic activities than that shown by PYY3−36 at 1000 nmol/kg in lean mice; therefore, the subsequent optimization of 5, 10, and 11 was performed in terms of the anorectic activity in lean mice. Design and Syntheses of Trp30-Ile31 Derivatives Substituted at the N-Terminus and at Positions 27 and 28. Further improvement of the anorectic activity of PYY analogues was examined by substitution at the N-terminus and at positions 27 and 28. For N-terminus substitutions, a cyclohexylcarbonyl analogue (13) of the Trp30-Ile31 derivatives showed similar in vitro activity and anorectic activity as the parent compound (5), indicating that an aromatic moiety of the N-terminus of dodecapeptide derivatives is not necessary for binding to Y2R. Although Cha introduction (14) at position 28 of 13 had some effect on the improvement of the anorectic activity, the binding affinity and agonist activity for Y2R were decreased. The 3-(2-naphthyl)alanine [Nal(2)]27 analogue (15) also possessed moderate anorectic activity but showed decreased in vitro activities. Design and Syntheses of Leu30-Aib31 and Trp30-Aib31 Derivatives Substituted at the N-Terminus and at Positions 27, 28, and 30. The N-terminal substitution of the Leu30-Aib31 analogue (10) with a cyclohexylcarbonyl moiety (16) showed no increase in either in vitro or in vivo activities. The cyclohexylcarbonyl analogue (17) of 11 composed of Trp30-Aib31 possessed a moderately improved anorectic activity compared to that of 11. Among the Leu30Aib31 derivatives substituted at position 28 (18−21), the Trp28 analogue (18) possessed relatively potent in vitro activities comparable to those of 10 but did not reduce the food intake at a dose of 500 nmol/kg in mice. Conversely, the replacement of an unnatural amino acid, 3-(1-naphthyl)alanine [Nal(1)] (19), Nal(2) (20), or Cha (21), at position 28 improved the anorectic activity at the dose of 500 nmol/kg. In particular, 21 showed the most robust activity at 49% food intake reduction. Even at a dose of 250 nmol/kg, an apparent anorectic effect of 21 was observed with a more potent activity than that of PYY3−36. When comparing the effect of replacing the Nterminal moiety (21−26), a benzoyl group (21) was preferable in terms of in vitro and in vivo activities. Although the introduction of a basic moiety at the N-terminus (24) increased the binding affinity and agonist activity for Y2R, 24 did not show increased anorectic activity compared with 21. A bulky hydrophobic moiety, such as 1-naphthoyl or 2-naphthoyl groups (25, 26), was not effective in increasing the binding affinity and agonist activity of the analogues for Y2R. Several preferable amino acid substitutions found in this study, for example, Trp30 (5), Phe(4F)30 (6), and Nal(2)27 (15), were also introduced into the basic structure of 22 containing a cyclohexanoyl moiety; however, these substitutions (27−29) did not lead to improved results in terms of food intake suppression. Anorectic Activity of PYY3−36, 1, and 21 in Lean Mice. The anorectic activity of PYY3−36, 1, and 21 was evaluated by bolus ip administration in lean mice (Table 2, Figure 1). PYY3−36 and 21 significantly reduced food intake 3 and 6 h after dosing in a dose-dependent manner with a minimum effective dose of 30 nmol/kg (ca. 52 μg/kg) (Table 2, Figure 1A), whereas weak anorectic activity of the lead compound, 1, with low serum stability was observed at a higher dose of 2000 nmol/kg (Table 1, Figure 1B). Compound 21 thus represented

Table 2. Food Intake Inhibitory Activities by Bolus Ip Administration of PYY3−36 and 21 % food intake inhibitiona time after administration (h) compound

dose (nmol/kg)

21 21 21 PYY3−36 PYY3−36 PYY3−36

3 30 300 3 30 300

3 −1 20 47 18 33 33

± ± ± ± ± ±

6 6 6 3 3 6 8

−1 18 45 13 26 20

± ± ± ± ± ±

24 2 3 2 2 2 8

−7 −2 8 −2 7 2

± ± ± ± ± ±

5 3 3 6 2 5

a

Percentage inhibition of cumulative food intake after administration of peptide analogues at doses of 3, 30, and 300 nmol/kg, as compared to that after ip injection with saline as a vehicle in male C57BL/6J mice. Data are expressed as mean ± SD (n = 5−6 per group).

a new short-length peptide that showed potent anorectic activity comparable to that of PYY3−36. Pharmacokinetic Parameters of 21 in Mice. The pharmacokinetic parameters of 21 were examined in lean mice. Compound 21 was injected intravenously (iv) and ip at 1 mg/kg (Table 3). The total body clearance (CLtotal) of 21 after iv administration was 162 mL/h/kg, indicating relatively low clearance compared to that of PYY3−36 (914 mL/h/kg) (Table S2). Compound 21 possessed lower tissue distribution than that of PYY3−36 (328 mL/kg) with a volume of distribution at steady state (Vdss) of 73 mL/kg. The pharmacokinetic properties of 21 were considered to be good in the blood circulation for such a short-length peptide and contributed the potent anorectic activity in mice, although the binding affinity and agonist activity of 21 were more than 10-fold lower than those of PYY3−36. The bioavailability (BA) value of 21 was 6.8 after ip dosing, indicating slow transfer into the blood vessels and the circulation. Thus, the possibility remains to obtain more potent analogues by increasing the absorption rate or improving the biological stability in peripheral tissues.

■

CONCLUSIONS We designed and synthesized short-length PYY3−36 analogues with 12 amino acid residues. A lead compound, benzoyl[Ala26,Ile28,31]PYY(25−36) (1), showed a moderate anorectic activity at a dose of 2000 nmol/kg in lean mice by ip administration. However, 1 showed low biological stability in the mouse serum. The substitution of an unnatural amino acid residue, Cha, at position 27 (2), 36 (3), or at both positions (4) of 1, improved the serum stability; notably, 4 was completely resistant to serum proteases under the condition of 20% mouse serum/PBS for 30 min. Furthermore, a bolus ip administration of 4 showed marked anorectic activity at a dose of 1000 nmol/ kg in mice. A subsequent investigation of the N-terminal modifications and amino acid substitutions at positions 27, 28, 30, and 31 led to the potent analogue (21) containing Cha28 and Aib31 residues. Compound 21, which exhibited a Y2R agonist activity comparable to that of 1, reduced food intake more potently than PYY3−36 at 300 nmol/kg in mice. Furthermore, ip-administered 21 inhibited food intake in a dose-dependent manner, with a minimum effective dose of 30 nmol/kg (ca. 52 μg/kg). Thus, the results of this study suggest that short-length PYY3−36 analogues without modification with PEG, albumin, or long-chain alkyl groups show potential as a new option of compounds with potent anorectic activity and an antiobesity effect. 2203

DOI: 10.1021/acsomega.7b00258 ACS Omega 2017, 2, 2200−2207

ACS Omega

Article

Figure 1. Anorectic activity of PYY3−36, 1, and 21 in lean mice. (A) Dose-dependent anorectic activity of PYY3−36 and 21 by ip administration. Food intake was measured at 3, 6, and 24 h post injection of PYY3−36 and 21 (3, 30, and 300 nmol/kg) in lean mice. Data are expressed as mean + SD (n = 5−6). #, P < 0.025 vs the vehicle (saline) group by the Williams test. (B) Anorectic activity of PYY3−36 and 1 by ip administration. Food intake was measured at 3, 6, and 24 h post injection of PYY3−36 (250 nmol/kg) and 1 (2000 nmol/kg) in lean mice. Data are expressed as mean +SD (n = 5−6). *, P < 0.05 vs the vehicle (saline) group by Student’s t test.

amino acid derivatives and resins were purchased from Novabiochem (Billerica, MA), Watanabe Chemical Industries (Hiroshima, Japan), Peptide Institute (Osaka, Japan), Bachem (Bubendorf, Switzerland), AnaSpec (Fremont, CA), ChemImpex International (Wood Dale, IL), and American Peptide Company (Sunnyvale, CA), whereas other reagents, such as coupling and deprotection reagents, were purchased from Wako Pure Chemical Industries (Osaka, Japan), Novabiochem, Watanabe Chemical Industries, and Nacalai Tesque (Kyoto, Japan). General Procedure for Synthesis of PYY Analogues. All peptides were synthesized in the same manner as the following synthesis procedure for benzoyl-[Cha27,28,36,Aib31]PYY(25−36) (21). Using commercially available Sieber Amide resin (347 mg, 0.25 mmol) as a starting material and an ABI433A peptide synthesizer (DCC/HOBt 0.25 mmol protocol), amino acids were successively condensed to give H-Arg(2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl, Pbf)-His(triphenylmethyl, Trt)-Cha-Cha-Asn(Trt)-Leu-AibThr(tert-butyl, tBu)-Arg(Pbf)-Gln(Trt)-Arg(Pbf)-Cha-Sieber Amide Resin (1.1292 g, 0.232 mmol/g). Then, 431.0 mg (0.1 mmol) of the obtained resin was weighed, washed with DMF, and after swelling, treated with benzoic acid (48.8 mg, 0.4 mmol), DIPCDI (63.6 μL, 0.4 mmol), and 0.5 M HOAt/DMF (0.8 mL, 0.4 mmol) in DMF for 90 min to benzoylate the Nterminus. The resin was washed with DMF and methanol and then dried to give benzoyl-Arg(Pbf)-His(Trt)-Cha-Cha-Asn(Trt)-Leu-Aib-Thr(tBu)-Arg(Pbf)-Gln(Trt)-Arg(Pbf)-ChaSieber Amide Resin (452.0 mg, 0.1 mmol). Next, TFA/ thioanisole/m-cresol/H2O/1,2-ethanedithiol/triisopropylsilane (80:5:5:5:2.5:2.5) (3 mL) was added to the entire amount of the obtained resin, and the mixture was stirred at an ambient temperature for 90 min, after which diethyl ether was added to the reaction solution to allow precipitation of a white powder. An operation to remove the ether by decantation after centrifugation of the suspension was repeated twice to remove the acid and scavenger material. The residue was extracted with an aqueous acetic acid solution and purified by preparative HPLC using Daisopak-SP100-5-ODS-P (20 × 250 mm I.D.) (OSAKA SODA, Osaka, Japan) to give 84.1 mg of a white

Table 3. Pharmacokinetic Parameters of 21 after Iv or Ip Administration in Micea compound 21 Iv C5 min (nmol/mL) AUC0−24 h (nmol h/mL) MRT (h) Vdss (mL/kg) CLtotal (mL/(h kg))

7548.3 3562.8 0.45 73 162 Ip

Cmax (nmol/mL) Tmax (h) AUC0−24 h (nmol h/mL) MRT (h) BA (%)

405.6 0.25 242.4 1.25 6.8

a Compound 21 was administered iv or ip to C57BL/6J mice at a dose of 1 mg/kg. Blood samples were collected at 5, 10, 15, 30 min, 1, 3, 6, 8, and 24 h after injection. Parameters were calculated from the mean (n = 3) plasma concentration−time profile. See the Experimental Section for further details.

■

EXPERIMENTAL SECTION Instruments and Materials. Manual Fmoc solid-phase peptide syntheses were conducted, which consisted of Fmoc cleavage with 20% piperidine/N,N-dimethylformamide (DMF) (20 min) and an Fmoc amino acid condensation reaction using N,N′-diisopropylcarbodiimide (DIPCDI)/1-hydroxy-7-azabenzotriazole (HOAt) (4 equiv), or by the ABI 433A automated peptide synthesizer (Applied Biosystems, Foster City, CA) [as per the Fmoc/DCC/N-hydroxybenzotriazole (HOBt) 0.25 mmol protocol]. All final compounds were purified to ≥95% homogeneity by the RP-HPLC analysis with a photodiode array detector across a wavelength range of 190−500 nm; the absence of co-eluting impurities (heterogeneous peaks) was confirmed by the liquid chromatography−mass spectrometry (LC/MS) analysis. The identity of the peptides was confirmed by the MALDI-TOF-MS analysis on a Bruker autoflex speed system (Billerica, MA). The purity, retention time, and molecular weight of each peptide are summarized in Table S1 of the Supporting Information. Commercially available 2204

DOI: 10.1021/acsomega.7b00258 ACS Omega 2017, 2, 2200−2207

ACS Omega

Article

1 μg protein/mL and 100 μL of 1 nM [35S]GTPγS (NEG030H, PerkinElmer). After incubation at room temperature for 120 min, the reaction mixture was filtered through a UniFilter-96 GF/C, washed, and dried, and the radioactivity was measured as done for the receptor binding assay. The data obtained were analyzed using Prism to calculate the EC50 value. Food Intake Assay. Male C57BL/6J mice (seven-weekold) were purchased from Charles River (Kanagawa, Japan). The mice were housed in a room at 22 °C in a 12 h light/12 h dark cycle and maintained on a standard chow diet. Before the administration of peptides, the mice were acclimated by daily handling for 5 days. They were then acclimated daily to ip injection by sham injection with a 29-gauge needle for 3 days. They were fasted for 16 h with water available during the dark cycle and then were ip injected with peptides. Preweighed chow was provided, and the food intake was measured at 3, 6, and 24 h post injection. Pharmacokinetics of PYY Analogues in Mice. Peptides were administered iv or ip to the C57BL/6J mice at a dose of 1 mg/kg in fed animals. After administration, blood samples were collected at 5, 10, 15, 30 min, 1, 3, 6, 8, and 24 h and centrifuged to obtain the plasma fraction. The plasma samples were deproteinized with acetonitrile, followed by centrifugation, and the supernatants were analyzed by LC/MC/MS to determine the plasma concentration of the peptides. The pharmacokinetics parameters were calculated by the moment analysis method. The plasma concentration 5 min after injection (C5 min), the area under the concentration−time curve from time zero to 24 h (AUC0−24 h), the mean residence time (MRT), Vdss, and CLtotal for each mouse after iv administration were obtained. The maximum plasma concentration (Cmax), time to maximum plasma concentration (Tmax), AUC 0−24 h , MRT, and BA for each mouse after ip administration were also obtained. Terminology. Abbreviations used for amino acids and designation of peptides follow the rules of the IUPAC-IUB Commission of Biochemical Nomenclature.37 Amino acid symbols denote the L-configuration unless indicated otherwise.

powder; mass spectrum: MALDI-TOF (α-cyano-4-hydroxycinnaminic acid, monoisotopic) [M + H]+ 1727.92 (Calcd 1728.05). Elution time on RP-HPLC: 8.19 min. Elution conditions: Phenomenex Kinetex 1.7 μm XB-C18 column (100 × 2.1 mm I.D.) (Torrance, CA), linear density gradient elution with eluents A/B = 95/5−45/55 (10 min), using 0.1% TFA in water as eluent A and 0.1% TFA-containing acetonitrile as eluent B; flow rate: 0.5 mL/min. Establishment of Cloned Human Y2R-Expressing CHO Cells. The entire coding region of the human NPY2R cDNA was amplified by the polymerase chain reaction (PCR) from human brain cDNA (TaKaRa Bio, Shiga, Japan). The DNA sequence of the PCR product was confirmed to represent human Y2R and finally cloned into expression vector pAKKO111H for the expression of Y2R in CHO cells. This expression vector was transfected into CHO (dhf r-) cells, and CHO cells stably expressing human Y2R were established as described previously.36 Membrane Preparation from CHO Cells Expressing Human Y2R. The affinity of the synthesized peptides for human Y2R was determined by a competitive binding experiment with membranes of CHO cells expressing cloned human Y2R. The membrane was prepared as described previously.36 The CHO cells were detached from the culture dish with PBS−ethylenediaminetetraacetic acid (EDTA). The cells were recovered by centrifugation at 1000 rpm for 10 min. The cell pellets obtained were homogenized in ice-cold homogenizing buffer [10 mM NaHCO3, 5 mM EDTA, 0.5 mM phenylmethylsulfonyl fluoride (PMSF), 10 μg/mL pepstatin A, 20 μg/mL leupeptin, 10 μg/mL E-64] with a Polytron homogenizer (Kinematica, Lucerne, Switzerland). The homogenate was centrifuged at 700g for 15 min at 4 °C, and then the supernatant obtained was ultracentrifuged at 10 000g for 60 min. The resultant pellet was suspended in a suspending buffer (50 mM Tris, 5 mM MgCl2, 150 mM NaCl, 0.5 mM PMSF, 10 μg/mL pepstatin A, 20 μg/mL leupeptin, 10 μg/mL E-64, 0.03% NaN3, pH 7.4). The protein concentration was determined using the Coomassie Plus Protein Assay Reagent (Thermo Fisher Scientific, Waltham, MA). Receptor Binding Assay for Human Y2R. First, 2 μL of the test compound was incubated in a 96-well plate with 100 μL of the membrane diluted with the assay buffer (50 mM Tris, 5 mM MgCl2, 150 mM NaCl, 0.03% NaN3, pH 7.4) to 0.5 μg protein/mL and 100 μL of 400 pM 125I-PYY (NEX341; PerkinElmer, Waltham, MA). After incubation at room temperature for 60 min, the reaction mixture was filtered through a UniFilter-96 GF/C (PerkinElmer) presoaked in a polyethylenimine (PEI) solution (20 mM Tris, 0.3% PEI, pH 7.4). The filter was washed three times with the ice-cold filtration buffer (50 mM Tris, 5 mM MgCl2, 150 mM NaCl, 0.03% NaN3, 0.05% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate, pH 7.4). The UniFilter-96 GF/C was then dried; 15 μL of the liquid scintillator MicroScint O (PerkinElmer) was then added to each well, and the radioactivity was measured using TopCount (PerkinElmer). The data obtained were analyzed using Prism (GraphPad Software, La Jolla, CA) to calculate the IC50 value. [35S]GTPγS Binding Assay. The agonist activity of the compounds for human Y2R was evaluated using a [35S]GTPγS binding assay. First, 2 μL of the test compound was incubated in a 96-well plate with 100 μL of the membrane diluted with the assay buffer (50 mM Tris, 5 mM MgCl2, 150 mM NaCl, 1 μL GDP, 0.03% NaN3, 0.1% bovine serum albumin, pH 7.4) to

■

ASSOCIATED CONTENT

S Supporting Information *

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acsomega.7b00258. Table S1, chemical data for dodecapeptide PYY analogues (PDF); Table S2, pharmacokinetic parameters of PYY3−36 (PDF) Molecular formula strings and the associated biochemical and biological data (CSV)

■

AUTHOR INFORMATION

Corresponding Author

*E-mail: [email protected]. Phone: +81-466-32-1186. Fax: +81-466-29-4453. ORCID

Taiji Asami: 0000-0001-5992-3166 Notes

The authors declare no competing financial interest.

■

ACKNOWLEDGMENTS We would like to thank Editage (www.editage.jp) for English language editing. 2205

DOI: 10.1021/acsomega.7b00258 ACS Omega 2017, 2, 2200−2207

ACS Omega

■

Article

bovine neuropeptide Y (NPY) receptor cDNA clone, or its human homologue, confers neither NPY binding sites nor NPY responsiveness on transfected cells. Regul. Pept. 1993, 47, 247−258. (14) Weinberg, D. H.; Sirinathsinghji, D. J.; Tan, C. P.; Shiao, L. L.; Morin, N.; Rigby, M. R.; Heavens, R. H.; Rapoport, D. R.; Bayne, M. L.; Cascieri, M. A.; Strader, C. D.; Linemeyer, D. L.; MacNeil, D. J. Cloning and expression of a novel neuropeptide Y receptor. J. Biol. Chem. 1996, 271, 16435−16438. (15) Matsumoto, M.; Nomura, T.; Momose, K.; Ikeda, Y.; Kondou, Y.; Akiho, H.; Togami, J.; Kimura, Y.; Okada, M.; Yamaguchi, T. Inactivation of a novel neuropeptide Y/peptide YY receptor gene in primate species. J. Biol. Chem. 1996, 271, 27217−27220. (16) Gregor, P.; Feng, Y.; DeCarr, L. B.; Cornfield, L. J.; McCaleb, M. L. Molecular characterization of a second mouse pancreatic polypeptide receptor and its inactivated human homologue. J. Biol. Chem. 1996, 271, 27776−27781. (17) Holzer, P.; Reichmann, F.; Farzi, A. Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut-brain axis. Neuropeptides 2012, 46, 261−274. (18) Pedragosa-Badia, X.; Stichel, J.; Beck-Sickinger, A. G. Neuropeptide Y receptors: how to get subtype selectivity. Front. Endocrinol. 2013, 4, No. 5. (19) Loh, K.; Herzog, H.; Shi, Y. C. Regulation of energy homeostasis by the NPY system. Trends Endocrinol. Metab. 2015, 26, 125−135. (20) Eberlein, G. A.; Eysselein, V. E.; Schaeffer, M.; Layer, P.; Grandt, D.; Goebell, H.; Niebel, W.; Davis, M.; Lee, T. D.; Shively, J. E.; Reeve, J. R., Jr. A new molecular form of PYY: structural characterization of human PYY(3−36) and PYY(1−36). Peptides 1989, 10, 797−803. (21) Grandt, D.; Schimiczek, M.; Beglinger, C.; Layer, P.; Goebell, H.; Eysselein, V. E.; Reeve, J. R., Jr. Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1−36 and PYY 3−36. Regul. Pept. 1994, 51, 151−159. (22) Keire, D. A.; Bowers, C. W.; Solomon, T. E.; Reeve, J. R., Jr. Structure and receptor binding of PYY analogs. Peptides 2002, 23, 305−321. (23) Batterham, R. L.; Cowley, M. A.; Small, C. J.; Herzog, H.; Cohen, M. A.; Dakin, C. L.; Wren, A. M.; Brynes, A. E.; Low, M. J.; Ghatei, M. A.; Cone, R. D.; Bloom, S. R. Gut hormone PYY(3−36) physiologically inhibits food intake. Nature 2002, 418, 650−654. (24) Sainsbury, A.; Schwarzer, C.; Couzens, M.; Fetissov, S.; Furtinger, S.; Jenkins, A.; Cox, H. M.; Sperk, G.; Hökfelt, T.; Herzog, H. Important role of hypothalamic Y2 receptors in body weight regulation revealed in conditional knockout mice. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 8938−8943. (25) Batterham, R. L.; Cohen, M. A.; Ellis, S. M.; Le Roux, C. W.; Withers, D. J.; Frost, G. S.; Ghatei, M. A.; Bloom, S. R. Inhibition of food intake in obese subjects by peptide YY3−36. N. Engl. J. Med. 2003, 349, 941−948. (26) Park, A.; Sileno, A.; Brandt, G.; Quay, S.; Bloom, S. Nasal peptide YY3−36: phase 1 dose ranging and safety study in healthy subjects. Int. J. Obes. 2004, 28, S222. (27) Lush, C.; Chen, K.; Hompesch, M.; Troupin, B.; LaCerte, C.; Burns, C.; Ellero, C.; Kornstein, J.; Vayser, I.; Wintle, M.; Blundell, J.; Baron, A.; Weyer, C. A phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of rising doses of AC162352 (synthetic human PYY3−36) in lean and obese subjects. Obes. Rev. 2005, 6, S21. (28) Balasubramaniam, A.; Servin, A. L.; Rigel, D. F.; Rouyer-Fessard, C. R.; Laburthe, M. Syntheses and receptor affinities of partial sequences of peptide YY (PYY). Pept. Res. 1988, 1, 32−35. (29) Koglin, N.; Zorn, C.; Beumer, R.; Cabrele, C.; Bubert, C.; Sewald, N.; Reiser, O.; Beck-Sickinger, A. G. Analogues of neuropeptide Y containing β-aminocyclopropane carboxylic acids are the shortest linear peptides that are selective for the Y1 receptor. Angew. Chem., Int. Ed. Engl. 2003, 42, 202−205. (30) Berlicki, L.; Kaske, M.; Gutiérrez-Abad, R.; Bernhardt, G.; Illa, O.; Ortuño, R. M.; Cabrele, C.; Buschauer, A.; Reiser, O. Replacement

REFERENCES

(1) Hu, F. B. Obesity Epidemiology; Oxford University Press: New York, 2008; pp 1−498. (2) Ng, M.; Fleming, T.; Robinson, M.; Thomson, B.; Graetz, N.; Margono, C.; Mullany, E. C.; Biryukov, S.; Abbafati, C.; Abera, S. F.; Abraham, J. P.; Abu-Rmeileh, N. M.; Achoki, T.; AlBuhairan, F. S.; Alemu, Z. A.; Alfonso, R.; Ali, M. K.; Ali, R.; Guzman, N. A.; Ammar, W.; Anwari, P.; Banerjee, A.; Barquera, S.; Basu, S.; Bennett, D. A.; Bhutta, Z.; Blore, J.; Cabral, N.; Nonato, I. C.; Chang, J. C.; Chowdhury, R.; Courville, K. J.; Criqui, M. H.; Cundiff, D. K.; Dabhadkar, K. C.; Dandona, L.; Davis, A.; Dayama, A.; Dharmaratne, S. D.; Ding, E. L.; Durrani, A. M.; Esteghamati, A.; Farzadfar, F.; Fay, D. F.; Feigin, V. L.; Flaxman, A.; Forouzanfar, M. H.; Goto, A.; Green, M. A.; Gupta, R.; Hafezi-Nejad, N.; Hankey, G. J.; Harewood, H. C.; Havmoeller, R.; Hay, S.; Hernandez, L.; Husseini, A.; Idrisov, B. T.; Ikeda, N.; Islami, F.; Jahangir, E.; Jassal, S. K.; Jee, S. H.; Jeffreys, M.; Jonas, J. B.; Kabagambe, E. K.; Khalifa, S. E.; Kengne, A. P.; Khader, Y. S.; Khang, Y. H.; Kim, D.; Kimokoti, R. W.; Kinge, J. M.; Kokubo, Y.; Kosen, S.; Kwan, G.; Lai, T.; Leinsalu, M.; Li, Y.; Liang, X.; Liu, S.; Logroscino, G.; Lotufo, P. A.; Lu, Y.; Ma, J.; Mainoo, N. K.; Mensah, G. A.; Merriman, T. R.; Mokdad, A. H.; Moschandreas, J.; Naghavi, M.; Naheed, A.; Nand, D.; Narayan, K. M.; Nelson, E. L.; Neuhouser, M. L.; Nisar, M. I.; Ohkubo, T.; Oti, S. O.; Pedroza, A.; Prabhakaran, D.; Roy, N.; Sampson, U.; Seo, H.; Sepanlou, S. G.; Shibuya, K.; Shiri, R.; Shiue, I.; Singh, G. M.; Singh, J. A.; Skirbekk, V.; Stapelberg, N. J.; Sturua, L.; Sykes, B. L.; Tobias, M.; Tran, B. X.; Trasande, L.; Toyoshima, H.; van de Vijver, S.; Vasankari, T. J.; Veerman, J. L.; Velasquez-Melendez, G.; Vlassov, V. V.; Vollset, S. E.; Vos, T.; Wang, C.; Wang, X.; Weiderpass, E.; Werdecker, A.; Wright, J. L.; Yang, Y. C.; Yatsuya, H.; Yoon, J.; Yoon, S. J.; Zhao, Y.; Zhou, M.; Zhu, S.; Lopez, A. D.; Murray, C. J.; Gakidou, E. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980−2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014, 384, 766−781. (3) Kelly, T.; Yang, W.; Chen, C. S.; Reynolds, K.; He, J. Global burden of obesity in 2005 and projections to 2030. Int. J. Obes. 2008, 32, 1431−1437. (4) Flegal, K. M.; Kit, B. K.; Orpana, H.; Graubard, B. I. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 2013, 309, 71−82. (5) Troke, R. C.; Tan, T. M.; Bloom, S. R. The future role of gut hormones in the treatment of obesity. Ther. Adv. Chronic Dis. 2014, 5, 4−14. (6) Mishra, A. K.; Dubey, V.; Ghosh, A. R. Obesity: An overview of possible role(s) of gut hormones, lipid sensing and gut microbiota. Metabolism 2016, 65, 48−65. (7) Tatemoto, K. Isolation and characterization of peptide YY (PYY), a candidate gut hormone that inhibits pancreatic exocrine secretion. Proc. Natl. Acad. Sci. U.S.A. 1982, 79, 2514−2518. (8) Michel, M. C.; Beck-Sickinger, A.; Cox, H.; Doods, H. N.; Herzog, H.; Larhammar, D.; Quirion, R.; Schwartz, T.; Westfall, T. XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol. Rev. 1998, 50, 143−150. (9) Larhammar, D.; Blomqvist, A. G.; Söderberg, C. Evolution of neuropeptide Y and its related peptides. Comp. Biochem. Physiol., Part C: Pharmacol., Toxicol. Endocrinol. 1993, 106, 743−752. (10) Larhammar, D. Evolution of neuropeptide Y, peptide YY and pancreatic polypeptide. Regul. Pept. 1996, 62, 1−11. (11) Rimland, J.; Xin, W.; Sweetnam, P.; Saijoh, K.; Nestler, E. J.; Duman, R. S. Sequence and expression of a neuropeptide Y receptor cDNA. Mol. Pharmacol. 1991, 40, 869−875. (12) Herzog, H.; Hort, Y. J.; Shine, J.; Selbie, L. A. Molecular cloning, characterization, and localization of the human homolog to the reported bovine NPY Y3 receptor: lack of NPY binding and activation. DNA Cell Biol. 1993, 12, 465−471. (13) Jazin, E. E.; Yoo, H.; Blomqvist, A. G.; Yee, F.; Weng, G.; Walker, M. W.; Salon, J.; Larhammar, D.; Wahlestedt, C. A proposed 2206

DOI: 10.1021/acsomega.7b00258 ACS Omega 2017, 2, 2200−2207

ACS Omega

Article

of Thr32 and Gln34 in the C-terminal neuropeptide Y fragment 25−36 by cis-cyclobutane and cis-cyclopentane β-amino acids shifts selectivity toward the Y4 receptor. J. Med. Chem. 2013, 56, 8422−8431. (31) DeCarr, L. B.; Buckholz, T. M.; Coish, P. D.; Fathi, Z.; Fisk, S. E.; Mays, M. R.; O’Connor, S. J.; Lumb, K. J. Identification of selective neuropeptide Y2 peptide agonists. Bioorg. Med. Chem. Lett. 2007, 17, 538−541. (32) Levy, O. E.; Jodka, C. M.; Ghosh, S. S.; Parkes, D.; Pittner, R. A.; D’Souza, L. J.; Ahn, J. S.; Prickett, K. S.; Roth, J. D.; Adams, S. H. Pancreatic Polypeptide Family Motifs, Polypeptides and Methods Comprising the Same. U.S. Patent 8,906,849, Dec 9, 2014. (33) Lumb, K. J.; DeCarr, L. B.; Milardo, L. F.; Mays, M. R.; Buckholz, T. M.; Fisk, S. E.; Pellegrino, C. M.; Ortiz, A. A.; Mahle, C. D. Novel selective neuropeptide Y2 receptor PEGylated peptide agonists reduce food intake and body weight in mice. J. Med. Chem. 2007, 50, 2264−2268. (34) DeCarr, L. B.; Buckholz, T. M.; Milardo, L. F.; Mays, M. R.; Ortiz, A.; Lumb, K. J. A long-acting selective neuropeptide Y2 receptor PEGylated peptide agonist reduces food intake in mice. Bioorg. Med. Chem. Lett. 2007, 17, 1916−1919. (35) Ortiz, A. A.; Milardo, L. F.; DeCarr, L. B.; Buckholz, T. M.; Mays, M. R.; Claus, T. H.; Livingston, J. N.; Mahle, C. D.; Lumb, K. J. A novel long-acting selective neuropeptide Y2 receptor polyethylene glycol-conjugated peptide agonist reduces food intake and body weight and improves glucose metabolism in rodents. J. Pharmacol. Exp. Ther. 2007, 323, 692−700. (36) Masuda, Y.; Sugo, T.; Kikuchi, T.; Kawata, A.; Satoh, M.; Fujisawa, Y.; Itoh, Y.; Wakimasu, M.; Ohtaki, T. Receptor binding and antagonist properties of a novel endothelin receptor antagonist, TAK044 {cyclo[D-α-aspartyl-3-[(4-phenylpiperazin-1-yl)carbonyl]-L-alanylL-α-aspartyl-D-2-(2-thienyl)glycyl-L-leucyl-D-tryptophyl]disodium salt}, in human endothelinA and endothelinB receptors. J. Pharmacol. Exp. Ther. 1996, 279, 675−685. (37) IUPAC-IUB Commission of Biochemical Nomenclature. Symbols for amino-acid derivatives and peptides. Recommendations (1971). J. Biol. Chem. 1972, 247, 977−983.

2207

DOI: 10.1021/acsomega.7b00258 ACS Omega 2017, 2, 2200−2207